Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 13;12(10):4802–4817. doi: 10.7150/thno.73746

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

PMC Copyright notice

Clinical characteristics of METTL3/LDHA axis on CRC progression. (A) The correlation of METTL3 and LDHA in 95 CRC tissues was analyzed. (B & C) METTL3 mRNA expression in CRC tumor tissues and normal tissues from Oncomine database of Skrzypczak (B) and Hong (C) CRC. (D & E) LDHA mRNA expression in CRC tumor tissues and normal tissues from Oncomine database of Skrzypczak (D) and Hong (E) CRC. (F & G) Relative protein expression of METTL3 (F) and LDHA (G) in stage II/III/IV CRC tissues based on data available from the CPTAC database. (H) OS in CRC patient with high (n=144) vs. low (n=115) levels of METTL3 was plotted by the Kaplan-Meier method. (I) OS in CRC patient with high (n=193) vs. low (n=66) levels of LDHA was plotted by the Kaplan-Meier method. (J) Proposed model to illustrate the mechanisms of METTL3/LDHA axis to trigger the glycolysis and chemoresistance of CRC cells.